Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports

We are conducting an adoptive immunotherapy (AIT) trial using zoledronate‐activated killer cells for patients in Japan with incurable cancer. We have encountered seven long‐term survivors. Since such long survival may be very rare in cancer treatment, we present the details and a discussion of a pos...

Descripción completa

Detalles Bibliográficos
Autor principal: Yamaguchi, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664521/
https://www.ncbi.nlm.nih.gov/pubmed/36397848
http://dx.doi.org/10.1002/ccr3.6540
_version_ 1784831118920384512
author Yamaguchi, Yoshiyuki
author_facet Yamaguchi, Yoshiyuki
author_sort Yamaguchi, Yoshiyuki
collection PubMed
description We are conducting an adoptive immunotherapy (AIT) trial using zoledronate‐activated killer cells for patients in Japan with incurable cancer. We have encountered seven long‐term survivors. Since such long survival may be very rare in cancer treatment, we present the details and a discussion of a possible role of AIT.
format Online
Article
Text
id pubmed-9664521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96645212022-11-16 Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports Yamaguchi, Yoshiyuki Clin Case Rep Case Report We are conducting an adoptive immunotherapy (AIT) trial using zoledronate‐activated killer cells for patients in Japan with incurable cancer. We have encountered seven long‐term survivors. Since such long survival may be very rare in cancer treatment, we present the details and a discussion of a possible role of AIT. John Wiley and Sons Inc. 2022-11-15 /pmc/articles/PMC9664521/ /pubmed/36397848 http://dx.doi.org/10.1002/ccr3.6540 Text en © 2022 The Author. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Yamaguchi, Yoshiyuki
Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
title Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
title_full Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
title_fullStr Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
title_full_unstemmed Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
title_short Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
title_sort long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: seven case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664521/
https://www.ncbi.nlm.nih.gov/pubmed/36397848
http://dx.doi.org/10.1002/ccr3.6540
work_keys_str_mv AT yamaguchiyoshiyuki longterm5yearsurvivorsamongunresectableormetastaticcancerpatientstreatedwithzoledronateactivatedkillercellssevencasereports

Ejemplares similares